Concerto doses first subject in Phase I trial of ENS-002 for atopic dermatitis
Concerto Biosciences leveraged its screening technology, kChip, for the discovery of ENS-002.
Therapy Area
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
Toragen reports positive results from trial of TGN-S11 for HPV-related cancer
Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis
Prostate cancer: Three drug trials to watch
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
AHA 2024: semaglutide continues to impress in diabetic kidney disease
How decentralisation can fill the gaps in Alzheimer’s research
